A perspective on treating type 1 diabetes mellitus before insulin is needed

Area of Science:

• Endocrinology and Metabolism
• Autoimmune Diseases
• Diabetes Research

Background:

• Type 1 diabetes mellitus (T1DM) is a progressive autoimmune condition.
• The American Diabetes Association defines T1DM in three stages, with stage 3 characterized by hyperglycemia.
• Early stage 3 T1DM, termed stage 3a, represents a non-insulin-dependent phase often unrecognized.

Purpose of the Study:

• To highlight the significance of early stage 3 T1DM (stage 3a) as a distinct clinical entity.
• To propose management strategies for individuals with stage 3a T1DM.
• To emphasize the potential for interventions to delay insulin initiation.

Main Methods:

• This is a perspective piece, not a clinical trial.
• It reviews current understanding of T1DM staging.
• It proposes a new classification (stage 3a) and discusses potential management approaches.

Main Results:

• Early stage 3 T1DM (stage 3a) is a period where individuals do not immediately require insulin.
• This phase offers a window for interventions to potentially delay insulin dependence.
• Management during stage 3a could reduce hypoglycemia risk and treatment burden.

Conclusions:

• Recognizing and managing stage 3a T1DM is crucial for optimizing patient care.
• Interventions during this phase may extend the insulin-free period.
• Further clinical trials are needed to validate management strategies for stage 3a T1DM.